Search results
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
Morningstar· 5 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
‘Walk and Rally’ works to defeat ALS
Tribune Chronicle· 4 days agoMore than 100 people line up at the starting point for Sunday’s 1-mile Trumbull County Walk & Rally to Defeat ALS through the Eastwood Mall concourse in...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D...
Morningstar· 2 days agoFN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National ...
Pitmasters Fire Up Fun At Second Roaring Camp Bbq Cook-Off
San Francisco Chronicle· 3 days agoThe third season of the wildly successful "BBQ Showdown" is set to debut on Independence Day on Netflix. There are many reasons for that popularity, said Rick Brandini, a competitive pitmaster ...
Stroller: Music and more wonders of coffee filters
Martinsville Bulletin· 17 hours agoTODAY’S WORD is mistral. The Spencer-Penn Centre asked the Stroller to remind everyone that tomorrow is Friday, June 14, and that means its Monthly Music Night at Spencer-Penn. The doors open ...
The Latest | Hamas responds to Gaza cease-fire plan, with 'remarks,' and US is evaluating
AOL· 3 days agoU.S. Secretary of State Antony Blinken called on Hamas on Tuesday to accept a U.S.-backed proposal for a Gaza cease-fire and hostage release, saying that the U.N. Security Council’s vote made ...
Accessing Alzheimer’s Disease care a long road for patients
Warren Times Observer· 4 days agoAs the prevalence of Alzheimer’s Disease and related cognitive conditions rises in Pennsylvania, advocates say prevention and more integrated systems of care are essential for meeting the demands ...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
The Pilot News· 5 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
